NRIX: Bull Flag detected on 13 Jul 2026

Bull flag forming with overall quality score of 78.6, comprising strong pattern structure (15.0/15) and solid volume metrics (12.0/12). Price currently at $23.06, consolidating between support at $22.33 and resistance at $24.88. Bollinger Band position at 0.655 indicates mid-range placement, while RSI at 65.26 shows momentum without overbought extremes. MACD histogram positive at 0.1741 supporting bullish momentum. Volume ratio of 0.61 reflects below-average participation. Prior patterns detected include ascending triangle (26.0 quality, 25 days) and bullish pennant (34.0 quality, 23 days), suggesting sustained upside building.

Nurix announced a global collaboration with Roche for bexobrutideg on June 8, 2026, with potential total payments up to $2.3 billion including $700 million upfront payment. On July 9, 2026, the company reported Q2 2026 results with pro-forma cash of approximately $1.14 billion including the expected $700 million upfront payment. Nurix reported 92.9% objective response rate in one chronic lymphocytic leukemia cohort, validating clinical efficacy. The collaboration includes a comprehensive clinical development plan in malignant hematology and expansion into chronic spontaneous urticaria and multiple sclerosis. This transformative partnership, announced just four days before Q2 earnings on July 9, provides major de-risking with milestone potential and substantially strengthens the balance sheet, explaining the 47% gain over one month.

Bull flag breakout above $24.88 resistance would target $23.82 on conservative basis per measured move, though historical flagging patterns often exceed initial targets. Successful breakout requires volume confirmation above the 20-day average of 2.57M shares—current volume of 1.55M indicates room for participation expansion. Win probability scores 75.77%, suggesting favorable odds. Invalidation occurs below support at $22.33; break below this level negates the bullish setup and signals reversal risk. Pattern structure quality scores maximum (15/15), supporting reliability of these levels.

Company faces uncertainties regarding ability to advance drug candidates, obtain regulatory approvals, and timing/results of preclinical and clinical trials. Roche collaboration agreement is subject to closing conditions and risks related to regulatory review, meaning $700M upfront remains contingent. Clinical trial execution risk remains elevated—Phase 3 DAYBreak CLL-306 dosing anticipated mid-2026 with no guaranteed enrollment or efficacy targets met. RSI at 65.26 approaching overbought (70), signaling potential near-term pullback risk. Volume ratio of 0.61 indicates weak participation; breakout may fail without institutional conviction. Biotech sector volatility elevated at 74.79% (20-day), increasing whipsaw risk. Recent 3.8% weekly loss despite monthly 47% gain suggests profit-taking pressure.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.